FCF Biotech
Venture Capital Monitor
-
USA

The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.

FCF Biotech Venture Capital Monitor - USA

As of the end of April 2021, we identify the following current VC trends in the US Biotech sector:

  • In 2021, overall Biotech funding in the USA has reached USD 12,828m so far
  • Top 5 deals exceed USD 330m each, largest transaction amounted to USD 735m in Treeline Biosciences, Inc.
  • Logos Capital (USA) leads the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and RA Capital Management (USA)
  • Oncology dominates as the top indication

RESEARCH

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

Licensing

Recent licensing trends of European Biotech companies in China
Upcoming
Recent licensing trends of European Biotech companies in China
Upcoming

Biotech Licensing Monitor – China
-Upcoming-
Recent licensing trends of European Biotech companies in China

NEWS & PRESS

Scroll Up